{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:43:14Z","timestamp":1794559394974,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.atherosclerosis.2023.117192","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T20:57:55Z","timestamp":1690577875000},"page":"117192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials"],"prefix":"10.1016","volume":"384","author":[{"given":"Anne C.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Hanselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.117192_bib1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/ijerph16071165","article-title":"Cardiovascular disease and the female disadvantage","volume":"16","author":"Woodward","year":"2019","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib3","doi-asserted-by":"crossref","first-page":"g5992","DOI":"10.1136\/bmj.g5992","article-title":"Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study","volume":"349","author":"Leening","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib4","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics - 2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.phrs.2017.01.025","article-title":"Gender differences in cardiovascular prophylaxis: focus on antiplatelet treatment","volume":"119","author":"Di Giosia","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2014.09.041","article-title":"Gender disparities in evidence-based statin therapy in patients with cardiovascular disease","volume":"115","author":"Virani","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/clc.23347","article-title":"Trends in prevalence of guideline-based use of lipid-lowering therapy in a large health system","volume":"43","author":"Sidebottom","year":"2020","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib8","first-page":"371","volume":"73","author":"\u015eim\u015fek","year":"2021","journal-title":"Rev. Invest. Clin."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib9","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.amjcard.2014.02.018","article-title":"Gender differences in achieving optimal lipid goals in patients with coronary artery disease","volume":"113","author":"Victor","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib10","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib11","article-title":"Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study","volume":"10","author":"Karalis","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Cholesterol Treatment Trialists' Collaboration Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib14","series-title":"NIASPAN (Niacin Extended-Release Tablets)","author":"Kos Pharmaceuticals","year":"2004"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib17","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024531","article-title":"Factors associated with enhanced low\u2010density lipoprotein cholesterol lowering with bempedoic acid","volume":"11","author":"Ballantyne","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib22","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028394","article-title":"Sex disparities in the effect of statins on lipid parameters: the PharmLines Initiative","volume":"101","author":"Hunt","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2047487320902750","article-title":"LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial","volume":"28","author":"Sever","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009221","article-title":"Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials","volume":"7","author":"Vallejo-Vaz","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib26","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.117192_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am. Heart J."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023050992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023050992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:28:42Z","timestamp":1762187322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023050992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":27,"alternative-id":["S0021915023050992"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117192","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117192"}}